Unintended target effect of anti-BCL-2 DNAi

INTRODUCTION: Previous research suggested that a novel compound PNT2258 inhibits B-cell lymphoma 2 (BCL-2) transcription by DNA interference (DNAi) and demonstrated its activity in preclinical xenograft models and in a pilot Phase II clinical trial in non-Hodgkin’s lymphoma (NHL). While the drug dow...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebrahim, Abdul Shukkur, Kandouz, Mustapha, Emara, Nada, Sugalski, Amara B, Lipovich, Leonard, Al-Katib, Ayad M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624602/
https://www.ncbi.nlm.nih.gov/pubmed/28989285
http://dx.doi.org/10.2147/CMAR.S139105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624602/
https://www.ncbi.nlm.nih.gov/pubmed/28989285
http://dx.doi.org/10.2147/CMAR.S139105

Ejemplares similares